胸腺五肽联合短程化疗治疗肺结核伴糖尿病患者效果探析.docVIP

胸腺五肽联合短程化疗治疗肺结核伴糖尿病患者的效果分析 　　【摘要】 目的：探索肺结核伴糖尿病患者应用胸腺五肽+短程化疗治疗的效果。方法：在笔者所在医院收治的肺结核伴糖尿病患者中选出129例作为本次研究对象，随机将患者分为治疗组（n=65）和对照组（n=64），对照组患者采用短程化疗疗法，治疗组在此基础上给予胸腺五肽治疗，对比分析两组患者的治疗效果。结果：治疗后，治疗组患者的总有效率为87.69%，显著高于对照组的75.00%，且病灶吸收的有效率为84.62%，高于对照组的70.31%，差异均有统计学意义（P0.05）。结论：胸腺五肽与短程化疗联合使用治疗肺结核伴糖尿病有助于提高治疗效果，促进病灶的吸收，控制血糖水平，具有临床应用价值 【关键词】 胸腺五肽； 短程化疗； 肺结核； 糖尿病 中图分类号 R521 文献标识码 B 文章编号 1674-6805（2016）22-0018-03 【Abstract】 Objective：To explore the effect of thymopentin and short course chemotherapy in the treatment of pulmonary tuberculosis with diabetes.Method：129 cases of pulmonary tuberculosis with diabetes mellitus in our hospital were selected as the objects，they were randomly divided into the treatment and control group，the control group was treated with the short course chemotherapy therapy，the treatment group based on given thymopentin treatment，the therapeutic effect of the two groups were compared and analyzed.Result：The total effective rate of treatment group was 87.69%，which significantly higher than 75.00% of the control group，and lesions absorb effective rate was 84.62%，which higher than 70.31% of control group，the differences were statistically significant（P0.05）.Conclusion： The combination of thymopentin and short course chemotherapy in the treatment of pulmonary tuberculosis with diabetes can help to improve the therapeutic effect，promote the absorption of lesions，control the blood glucose level，and has clinical application value. 【Key words】 Thymopentin； Short course chemotherapy； Tuberculosis； Diabetes First-authors address：Chest Hospital of Xinjiang Uygur Autonomous Region，Urumqi 830049，China doi：10.14033/j.cnki.cfmr.2016.22.008 有流行病学调查研究显示：我国的肺结核伴糖尿病发病率近年来有明显上升趋势，多发于40～60岁中老年人。其中肺结核并发糖尿病的发病率在5%～15%，糖尿病并发肺结核的发病率则比正常人并发肺结核的发病率高出5～10倍。这一研究结果说明肺结核与糖尿病之间存在一定的相关性[1-2]。肺结核伴糖尿病的常规疗法是短程化疗，笔者所在医院将该疗法与胸腺五肽联合起来应用，有效提高了治疗效果，现报道如下 1 资料与方法 1.1 一般资料 选取2012年7月-2015年8月笔者所在医院收治的肺结核伴糖尿病患者129例作为研究对象，将其随机分为治疗组和对照组。治疗组65例患者，男29例，女36例，年龄45～62岁，平均（52.4±11.7）岁；